ProMIS Neurosciences, Inc. (PMN)

The immediate outlook is severely clouded by a relentless downward price trend over the last four consecutive years, culminating in a catastrophic 91.8% loss of value since 2016. While recent headlines celebrate promising Alzheimer's trial data and analyst upgrades, the market has already priced in a structural deterioration that the stock cannot currently reverse. The price action over the past two weeks confirms this weakness, with shares sliding from $13.58 to $9.61 despite the positive news cycle, indicating that the fundamental reality of the business—characterized by negative earnings, negative free cash flow, and a return on equity of -172%—remains a heavy anchor. With no dividend to provide income and a balance sheet showing significant cash burn, the investment case relies entirely on a speculative turnaround that has yet to materialize in the share price. The statistical forecast offers almost no guidance, reflecting the high volatility and uncertainty surrounding this biotech play. Until the company demonstrates sustained profitability or a clear path to cash flow positivity, the risk of permanent capital loss outweighs the potential for recovery.